The peptic ulcer and gastro-oesophageal reflux disease (GORD) medicine market in Canada is expected to experience a steady decline from 2024 to 2028. Forecasted data suggests a consistent decrease in market sales value, indicating a year-on-year decline of approximately 5.9% from 2024 to 2028.

In 2023, the market value was higher, hinting at potential saturation or increased market competition affecting future sales. The five-year CAGR reveals a contraction in market value, averaging around 6.7% per year from 2024 onwards.

**Future Trends to Watch For:**

Emerging alternative treatments that could shift market dynamics.
Changes in healthcare policies affecting drug pricing and consumption.
Technological advancements and innovations in disease management.
Increasing competition from generic pharmaceuticals impacting branded medicine sales.